Hypoxia inducible factor-1α induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-xL
- 19 October 2012
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (5) , 1048-1055
Abstract
Non-Hodgkin lymphoma (NHL) is one of the most common cancers in childhood. The development of chemoresistance in tumor cells is one of the principal causes of treatment failure. This resistance has been associated with different mechanisms, one being the overexpression of anti-apoptotic proteins such as Bcl-xL. It has been shown that this protein is regulated by the transcription factor hypoxia inducible factor-1α (HIF-1α), which is overexpressed in several tumors including NHL, and the overexpression of both proteins may result in resistance to chemotherapy. We investigated the role of HIF-1α in resistance to chemotherapy via the induction of Bcl-xL expression in NHL cell lines, using a pharmacological modulation of HIF-1α. Our data showed that treating Ramos cells with ethyl 3,4-dihydroxybenzoate, an inhibitor of prolyl hydroxylase, induces accumulation of HIF-1α and this correlates with an increase of Bcl-xL as well as resistance to apoptosis after exposure to chemotherapeutics drugs. In contrast, the treatment of Ramos cells with 2-methoxyestradiol, an inhibitor of HIF-1α activity, induced down-regulation of Bcl-xL expression, and this correlated with the sensitization of tumor cells to chemotherapeutic drugs. These data demonstrate that up-regulation of the anti-apoptotic protein Bcl-xL in NHL cells correlates with HIF-1α expression and activity, through which a phenotype of chemoresistance is induced.Keywords
This publication has 35 references indexed in Scilit:
- Childhood cancer mortality in America, Asia, and Oceania, 1970 through 2007Cancer, 2010
- Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphomaAnnals of Oncology, 2010
- Epidemiology of childhood cancerCancer Treatment Reviews, 2010
- Bcl-xL Gene Expression Correlated with Lower Apoptotic Cell Numbers and Shorter Progression-Free Survival in PCFCLJournal of Investigative Dermatology, 2009
- Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma modelMolecular Cancer, 2008
- Suppression of Bcl-xL expression by a novel tumor-specific RNA interference system inhibits proliferation and enhances radiosensitivity in prostatic carcinoma cellsCancer Chemotherapy and Pharmacology, 2007
- Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells☆Gynecologic Oncology, 2007
- Advanced-Stage Large-Cell Lymphoma in Children and Adolescents: Results of a Randomized Trial Incorporating Intermediate-Dose Methotrexate and High-Dose Cytarabine in the Maintenance Phase of the APO Regimen: A Pediatric Oncology Group Phase III TrialJournal of Clinical Oncology, 2005
- Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphomaBlood, 2004
- Bak BH3 Peptides Antagonize Bcl-xL Function and Induce Apoptosis through Cytochrome c-independent Activation of CaspasesJournal of Biological Chemistry, 1999